还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

- t0 O2 M( c. Z0 h/ }5 g+ ^4 \+ |                               
登录/注册后可看大图

5 F6 ^0 L) R9 f- \+ X/ i) T/ F% n请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
' \1 P: ]/ ^$ P1 K5 x
+ I8 r, o! H6 @/ c0 r  z9 P/ N' G* t, S
Sub-category:
Molecular Targets
5 H3 ~, B9 b1 n
3 B' E6 O6 {2 L4 ^+ t  t! n
2 G6 V2 K0 l8 Q9 r* NCategory:
Tumor Biology
4 b% S! F( B$ F; i, W4 C, V* K
% `' A, c$ M+ T$ Z
Meeting:
# ~; ~' }! K7 Y6 t8 i2011 ASCO Annual Meeting
) F4 ^4 o/ O( w8 ?" }4 l

Session Type and Session Title:
Poster Discussion Session, Tumor Biology
$ m' E8 _$ H$ y: D% N6 z" m# r7 \

Abstract No:
$ x0 b" s% \0 |+ ]& i% A10517


Citation:
" z6 \% v! K8 T  p2 JJ Clin Oncol 29: 2011 (suppl; abstr 10517)


Author(s):
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China


' m0 b* m% X/ k  w, D" b
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

Abstract Disclosures

: D5 K, Z% m6 K+ AAbstract:

' v' M  r8 ~9 U* d
- b" u- j6 a) ?& D7 Z1 P7 WBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

3 t  f( i6 {. ^* n# H8 O                               
登录/注册后可看大图

+ T: K( G8 G& Z( ~9 j  T# j没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

/ T6 |- `2 a- g1 \& M/ A- x化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？
6 u  J# k, O* n2 y
1 x8 v0 N$ ?/ b& v1 Z  a) ?" J现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊